Anti-PCSK9 Reference Antibody (alirocumab) is a recombinant monoclonal antibody that specifically targets and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It serves as a reference standard mimicking the therapeutic antibody alirocumab, primarily used in research settings for in vitro applications such as binding assays, neutralization studies, ELISA, and pharmacokinetic/pharmacodynamic evaluations. This reagent aids in the development and validation of PCSK9-targeted therapies for hypercholesterolemia and cardiovascular disease research, but is not intended for direct clinical use in patients.